{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:22:31Z","timestamp":1793830951524,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3631-8","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T05:55:20Z","timestamp":1504590920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population"],"prefix":"10.1186","volume":"17","author":[{"given":"Sanna","family":"Hallamies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa M.","family":"Pelttari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Poikonen-Saksela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Jekunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"Jukkola-Vuorinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"Auvinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Blomqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiina","family":"Aittom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-2976","authenticated-orcid":false,"given":"Heli","family":"Nevanlinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"3631_CR1","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/his.12862","volume":"68","author":"S Deb","year":"2016","unstructured":"Deb S, Lakhani SR, Ottini L, Fox SB. The cancer genetics and pathology of male breast cancer. Histopathology. 2016;68:110\u20138.","journal-title":"Histopathology"},{"key":"3631_CR2","doi-asserted-by":"crossref","unstructured":"Brinton LA, Richesson DA, Gierach GL, Lacey JV, Jr., Park Y, Hollenbeck AR, Schatzkin A. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 2008;100:1477\u20131481.","DOI":"10.1093\/jnci\/djn329"},{"key":"3631_CR3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1593\/neo.04193","volume":"6","author":"K Syrj\u00e4koski","year":"2004","unstructured":"Syrj\u00e4koski K, Kuukasj\u00e4rvi T, Waltering K, Haraldsson K, Auvinen A, Borg \u00c5, Kainu T, Kallioniemi OP, Koivisto PA. BRCA2 mutations in 154 finnish male breast cancer patients. Neoplasia 2004;6:541\u2013545.","journal-title":"Neoplasia"},{"key":"3631_CR4","volume":"10","author":"ET Lim","year":"2014","unstructured":"Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstr\u00f6m K, Esko T, Magi R, Inouye M, Lappalainen T, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 2014;10:e1004494.","journal-title":"PLoS Genet."},{"key":"3631_CR5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.ejhg.5200529","volume":"8","author":"L Sarantaus","year":"2000","unstructured":"Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrj\u00e4koski K, Kainu T, Vahteristo P, et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur J Hum Genet. 2000;8:757\u201363.","journal-title":"Eur J Hum Genet."},{"key":"3631_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, Van Veghel-Plandsoen M, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55\u20139.","journal-title":"Nat Genet"},{"key":"3631_CR7","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/sj.onc.1209877","volume":"25","author":"H Nevanlinna","year":"2006","unstructured":"Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006;25:5912\u20139.","journal-title":"Oncogene"},{"key":"3631_CR8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/341943","volume":"71","author":"P Vahteristo","year":"2002","unstructured":"Vahteristo P, Bartkova J, Eerola H, Syrj\u00e4koski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittom\u00e4ki K, Heikkil\u00e4 P, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71:432\u20138.","journal-title":"Am J Hum Genet."},{"key":"3631_CR9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ijc.11384","volume":"108","author":"K Syrj\u00e4koski","year":"2004","unstructured":"Syrj\u00e4koski K, Kuukasj\u00e4rvi T, Auvinen A, Kallioniemi OP. CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer. 2004;108:475\u20136.","journal-title":"Int J Cancer."},{"key":"3631_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-008-0162-7","volume":"116","author":"M Wasielewski","year":"2009","unstructured":"Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat. 2009;116:397\u2013400.","journal-title":"Breast Cancer Res Treat"},{"key":"3631_CR11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10549-016-4085-4","volume":"161","author":"M Pritzlaff","year":"2017","unstructured":"Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, Goldgar DE, Shimelis H, Couch FJ, Chao EC, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat. 2017;161:575\u201386.","journal-title":"Breast Cancer Res Treat"},{"key":"3631_CR12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ijc.20299","volume":"111","author":"O Kilpivaara","year":"2004","unstructured":"Kilpivaara O, Vahteristo P, Falck J, Syrj\u00e4koski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkil\u00e4 P, Aittom\u00e4ki K, et al. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer. 2004;111:543\u20137.","journal-title":"Int J Cancer."},{"key":"3631_CR13","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"3631_CR14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.blre.2016.10.002","volume":"31","author":"NE Mamrak","year":"2017","unstructured":"Mamrak NE, Shimamura A, Howlett NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev. 2017;31:93\u20139.","journal-title":"Blood Rev"},{"key":"3631_CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117\u201330.","journal-title":"Am J Hum Genet"},{"key":"3631_CR16","doi-asserted-by":"crossref","unstructured":"Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP, Fraser L, Gentry-Maharaj A, Hayward J, Philpott S, et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst. 2015;107:djv214.","DOI":"10.1093\/jnci\/djv214"},{"key":"3631_CR17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylk\u00e4s K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497\u2013506.","journal-title":"N Engl J Med."},{"key":"3631_CR18","doi-asserted-by":"crossref","unstructured":"Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittom\u00e4ki K, B\u00fctzow R, Nevanlinna H. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet 2011;20:3278\u20133288.","DOI":"10.1093\/hmg\/ddr229"},{"key":"3631_CR19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2224","volume":"44","author":"C Loveday","year":"2012","unstructured":"Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, Warren-Perry M, Snape K, Eccles D, Evans DG, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44:475\u20136.","journal-title":"Nat Genet"},{"key":"3631_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/2159-8290.CD-14-1156","volume":"5","author":"SL Sawyer","year":"2015","unstructured":"Sawyer SL, Tian L, Kahkonen M, Schwartzentruber J, Kircher M, Majewski J, Dyment DA, Innes AM, Boycott KM, Moreau LA, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015;5:135\u201342.","journal-title":"Cancer Discov"},{"key":"3631_CR21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature05609","volume":"446","author":"H Erkko","year":"2007","unstructured":"Erkko H, Xia B, Nikkil\u00e4 J, Schleutker J, Syrj\u00e4koski K, Mannermaa A, Kallioniemi A, Pylk\u00e4s K, Karppinen SM, Rapakko K, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316\u20139.","journal-title":"Nature."},{"key":"3631_CR22","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, K\u00e4rkk\u00e4inen H, Aaltonen K, Milne RL, Heikkil\u00e4 P, Aittom\u00e4ki K, Blomqvist C, Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009;15:3214\u201322.","journal-title":"Clin Cancer Res."},{"key":"3631_CR23","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/ng.893","volume":"43","author":"C Loveday","year":"2011","unstructured":"Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43:879\u201382.","journal-title":"Nat Genet"},{"key":"3631_CR24","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/jmedgenet-2012-100852","volume":"49","author":"LM Pelttari","year":"2012","unstructured":"Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, Leminen A, Heikkil\u00e4 P, Blomqvist C, et al. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer. J Med Genet. 2012;49:429\u201332.","journal-title":"J Med Genet."},{"key":"3631_CR25","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.1407909111","volume":"111","author":"JI Kiiski","year":"2014","unstructured":"Kiiski JI, Pelttari LM, Khan S, Freysteinsdottir ES, Reynisdottir I, Hart SN, Shimelis H, Vilske S, Kallioniemi A, Schleutker J, et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A. 2014;111:15172\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3631_CR26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.155","volume":"40","author":"R Fagerholm","year":"2008","unstructured":"Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrj\u00e4koski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40:844\u20133.","journal-title":"Nat Genet."},{"key":"3631_CR27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/jmg.2004.019737","volume":"41","author":"GH Bock de","year":"2004","unstructured":"de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, et al. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004;41:731\u20135.","journal-title":"J Med Genet"},{"key":"3631_CR28","doi-asserted-by":"crossref","unstructured":"Hale V, Weischer M, Park JY. CHEK2 ( *) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer 2014;2014:294575.","DOI":"10.1155\/2014\/294575"},{"key":"3631_CR29","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10549-007-9878-z","volume":"112","author":"DH Choi","year":"2008","unstructured":"Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat. 2008;112:569\u201373.","journal-title":"Breast Cancer Res Treat"},{"key":"3631_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2350-4-1","volume":"4","author":"K Offit","year":"2003","unstructured":"Offit K, Pierce H, Kirchhoff T, Kolachana P, Rapaport B, Gregersen P, Johnson S, Yossepowitch O, Huang H, Satagopan J, et al. Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC Med Genet. 2003;4:1.","journal-title":"BMC Med Genet"},{"key":"3631_CR31","doi-asserted-by":"crossref","unstructured":"Ohayon T, Gal I, Baruch RG, Szabo C, Friedman E. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004;108:479\u2013480.","DOI":"10.1002\/ijc.11603"},{"key":"3631_CR32","doi-asserted-by":"crossref","unstructured":"Neuhausen S, Dunning A, Steele L, Yakumo K, Hoffman M, Szabo C. Tee L, Baines C, Pharoah P, Goldgar D, et al. Role of CHEK2*1100delC in unselected series of non-BRCA1\/2 male breast cancers. Int J Cancer. 2004;108:477\u20138.","DOI":"10.1002\/ijc.11385"},{"key":"3631_CR33","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/bcr2823","volume":"13","author":"V Silvestri","year":"2011","unstructured":"Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Palli D, Ottini L. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res. 2011;13:404.","journal-title":"Breast Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3631-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T05:55:38Z","timestamp":1504590938000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3631-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3631"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3631-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]},"article-number":"620"}}